Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer

被引：7
作者：
Gondo, Miki [1 ]
Sakai, Tsutomu [1 ]
Tsuneoka, Hiroshi [1 ]
Kanehira, Chihiro [2 ]
机构：
[1] Jikei Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan
[2] Jikei Univ, Div Radiol, Sch Med, Tokyo, Japan
来源：
CLINICAL OPHTHALMOLOGY | 2011年 / 5卷
关键词：
bevacizumab; radiation; maculopathy; papillopathy;
D O I：
10.2147/OPTH.S23650
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Background: The evaluation of intravitreal bevacizumab treatment for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer. Case report: A patient with radiation maculopathy and papillopathy was treated with intravitreal bevacizumab (1.25 mg). Main outcome measures included fundus photography, angiography, and optical coherence tomography (OCT). Two weeks after intravitreal bevacizumab, visual acuity improved from 0.4 to 1.2. Fundus examination revealed decreased disc swelling, peripapillary hemorrhage, and macular edema. OCT demonstrated complete resolution of serous retinal detachment. At the 12-month follow-up, there was no exudation recurrence. No ocular or systemic side effects were observed. Conclusion: Intravitreal bevacizumab can be used to treat radiation maculopathy and papillopathy. Antivascular endothelial growth factor therapy may decrease tissue injury associated with radiation vasculopathy.
引用
收藏
页码：1217 / 1219
页数：3
相关论文
共 13 条
[1]   Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration [J].
Avery, RL ;
Pieramici, DJ ;
Rabena, MD ;
Castellarin, AA ;
Nasir, MA ;
Giust, MJ .
OPHTHALMOLOGY, 2006, 113 (03) :363-372
[2]   ANALYSIS OF VISION LOSS CAUSED BY RADIATION-INDUCED OPTIC NEUROPATHY AFTER PARTICLE THERAPY FOR HEAD-AND-NECK AND SKULL-BASE TUMORS ADJACENT TO OPTIC NERVES [J].
Demizu, Yusuke ;
Murakami, Masao ;
Miyawaki, Daisuke ;
Niwa, Yasue ;
Akagi, Takashi ;
Sasaki, Ryohei ;
Terashima, Kazuki ;
Suga, Daisaku ;
Kamae, Isao ;
Hishikawa, Yoshio .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (05) :1487-1492
[3]   Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy [J].
Finger, Paul T. ;
Chin, Kimberly .
ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (06) :751-756
[4]   Anti-VEGF bevacizumab (Avastin®) for radiation optic neuropathy [J].
Finger, Paul T. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 143 (02) :335-338
[5]   Intravitreous Ranibizumab (Lucentis) for Radiation Maculopathy [J].
Finger, Paul T. ;
Chin, Kimberly J. .
ARCHIVES OF OPHTHALMOLOGY, 2010, 128 (02) :249-252
[6]   Risk factors for radiation maculopathy and papillopathy after intraocular irradiation [J].
Gragoudas, ES ;
Li, WJ ;
Lane, AM ;
Munzenrider, J ;
Egan, KM .
OPHTHALMOLOGY, 1999, 106 (08) :1571-1577
[7]   Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin) [J].
Gupta, Aanchal ;
Muecke, James S. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2008, 28 (07) :964-968
[8]   Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema [J].
Haritoglou, Christos ;
Kook, Daniel ;
Neubauer, Aljoscha ;
Wolf, Armin ;
Priglinger, Siegfried ;
Strauss, Rupert ;
Gandorfer, Arnd ;
Ulbig, Michael ;
Kampik, Anselm .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (09) :999-1005
[9]  
Hopewell JW, 1998, MED PEDIATR ONCOL, P1
[10]   Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion - A short-term study [J].
Iturralde, Diana ;
Spaide, Richard F. ;
Meyerle, Catherine B. ;
Klancnik, Jay M. ;
Yannuzzi, Lawrence A. ;
Fisher, Yale L. ;
Sorenson, John ;
Slakter, Jason S. ;
Freund, K. Bailey ;
Cooney, Michael ;
Fine, Howard F. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03) :279-284
12